MENU

Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Ablynx and Merck Serono enter into an agreement to co-discover and co-develop Nanobodies®

Abstract:
Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies® against two targets in oncology and immunology and equally share the resulting profits

Ablynx and Merck Serono enter into an agreement to co-discover and co-develop Nanobodies®

Ghent, BELGIUM | Posted on September 4th, 2008

Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has entered into an agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to co-discover and co-develop Nanobodies® against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of EUR 10 million.

Nanobodies® are a new class of therapeutic proteins that contain the unique structural and functional properties of naturally-occurring single domain antibodies. The partners will collaborate to research and develop Nanobody®-based therapeutics against two disease targets exploiting some of the key benefits Nanobodies® have over conventional antibodies and other fragments.

Under the terms of the agreement, both companies will equally share all research and development costs. Should Ablynx contribute equally to each program, it will be eligible to receive fifty percent of the resulting profits. In addition, Ablynx will have an option to opt-out partly or fully during the research and development programs, in which case the company would be eligible to receive either a reduced profit share, in the case of a partial opt-out, or milestones and royalties on potential sales, in the case of a full opt-out. Total development and commercial milestones, depending on the point of opt-out by Ablynx, could reach up to EUR 325 million should a product be approved in multiple indications in all major markets.

"This collaboration reinforces our commitment to deliver innovative treatments in areas of high unmet medical needs," said Dr Bernhard Kirschbaum, Executive Vice President Research of Merck Serono. "We believe that Nanobodies® have the potential to provide innovative drugs combining the best features of monoclonal antibodies and small molecules, and we look forward to working with Ablynx."

####

For more information, please click here

Contacts:
For more information, please contact:
College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, John McIntyre
t: +44 (0)20 7866 7857
f: +44 (0)20 7866 7900
e: ablynx@collegehill.com


Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Portable Raman analyzer detects hydrogen leaks from a distance: Device senses tiny concentration changes of hydrogen in ambient air, offering a dependable way to detect and locate leaks in pipelines and industrial systems April 25th, 2025

Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025

Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025

Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025

Nanomedicine

Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025

Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes April 25th, 2025

Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025

Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025

Announcements

Portable Raman analyzer detects hydrogen leaks from a distance: Device senses tiny concentration changes of hydrogen in ambient air, offering a dependable way to detect and locate leaks in pipelines and industrial systems April 25th, 2025

Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025

Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025

Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025

Alliances/Trade associations/Partnerships/Distributorships

Manchester graphene spin-out signs $1billion game-changing deal to help tackle global sustainability challenges: Landmark deal for the commercialisation of graphene April 14th, 2023

Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022

Research partnerships

HKU physicists uncover hidden order in the quantum world through deconfined quantum critical points April 25th, 2025

SMART researchers pioneer first-of-its-kind nanosensor for real-time iron detection in plants February 28th, 2025

Gene therapy relieves back pain, repairs damaged disc in mice: Study suggests nanocarriers loaded with DNA could replace opioids May 17th, 2024

Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project